Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

EST: Adds comments from Seeking Alpha analyst BioCGT Investor Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

French company DNA Script will contribute its enzymatic DNA synthesis technologies, while Quantoom of Belgium will bring its ...

Genetic engineering deployed to insert gene for human insulin into a bacterium, thus harnessing the substance for widespread ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...